Bilici, Mehmet

Prognostic Value of Albumin-to-CEA Ratio in Metastatic Colorectal Cancer: A Retrospective Study

Parameters That May Predict NAC Effectiveness in Hormone-Positive Breast Cancer According to CPS Score

The frequency of driver mutations in non-small cell lung cancer patients: The Turkish nation-wide, observational, Registurk-Lung study (updated analysis).

New Parameters That May Predict Tumor Regression and Survival in Neoadjuvant Chemoradiotherapy in Locally Advanced Rectal Cancer

Prognostic Value of the PILE Score in Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Chemoradiotherapy

Bridging East and West: Real-World Clinicogenomic Landscape of Metastatic NSCLC in Türkiye

The Relationship Between Vitamin D and Euthyroid Sick Syndrome in Hospitalized Solid Cancer Patients: A Retrospective Study

"Pre-Treatment" and "Post-Treatment" Systemic Inflammatory Markers: Is There Any Prognostic Role for Metastatic Cervical Cancer on Bevacizumab Containing Treatment?

Pembrolizumab in HER2-Positive Gastric Cancer

Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study

Health-related quality of life (HRQOL) with pembrolizumab (pembro) plus trastuzumab (tras) and chemotherapy (chemo) in first-line HER2-positive (HER2+) advanced gastric cancer: KEYNOTE-811 trial results

Pathological complete response (pCR) to 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) with or without durvalumab (D) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study

The results of adding immunotherapy to chemotherapy in patients with small cell lung cancer: Registurk-Lung study-Real-world data

The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker

A novel prognostic biomarker in progression free survival for patients with cervical cancer, glucose to c-reactive protein ratio (GCR)

Inflammatory parameters in NSCLC with driver mutation

Pathological complete response to FLOT chemotherapy with/without durvalumab in resectable gastric and gastroesophageal junction cancer:subgroup analysis by region from the phase 3, randomized, double-blind MATTERHORN study

Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial

The value of pretreatment glucose-to-lymphocyte ratio for predicting survival of metastatic gastric cancer

Reply to John L. Frater's letter to the editor: Use of laboratory hematology data in melanoma research: comments on 'A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio'

Lipegfilgrastim may cause hyperleukocytosis

A novel prognostic biomarker for cutaneous malignant melanoma: red cell distribution width (RDW) to lymphocyte ratio

The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib

Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience

The comparison of FOLFOX regimens with different doses of 5-FU for the adjuvant treatment of colorectal cancer: a multicenter study

Pazopanib for metastatic soft-tissue sarcoma: A multicenter retrospective study